BioNTX Welcomes Caroline Griffin to Strengthen
Member Engagement and Community Connections
|
Meet BioNTX’s new Membership & Ecosystem Engagement Manager
BioNTX is excited to welcome Caroline Griffin to the team. In her new role, Caroline will focus on strengthening member relationships, expanding ecosystem engagement, and supporting connections across the North Texas life sciences and healthcare innovation community.
Caroline brings experience in marketing strategy, business development, and stakeholder engagement. Her background in building partnerships and creating strategic marketing initiatives will support BioNTX’s efforts to strengthen connections across the life sciences ecosystem.
We are thrilled to have Caroline join BioNTX and look forward to the impact she will make as we continue to grow and support our members.
|
Share Your Open Jobs with BioNTX Today
|
BioNTX members, are you hiring?
|
Send us your current job openings today so we can promote them to qualified job seekers attending Congresswoman Beth Van Duyne's 5th Annual North Texas Job Fair on August 6.
BioNTX will be participating in the job fair to highlight the growing life sciences ecosystem in North Texas and connect talented professionals with career opportunities at our member organizations and partner companies. This is a great opportunity to increase the visibility of your open positions with professionals interested in careers in the life sciences industry.
|
Take Your Biotech Idea to the Next Level
with Alloy Futures Startup Academy
Applications closes on August 23, 2026
|
Applications for the third cohort of the Alloy Futures Biotech Startup Academy are now open!
This immersive seven-week hybrid program, offered both in person at BioLabs and online, is designed for emerging biotech founders and aspiring life science entrepreneurs. Participants will gain the knowledge, practical tools, and industry connections needed to advance their ideas and navigate the challenges of building a life science startup.
|
Join Us This September at the 2026 iC³ Summit
September 24 - 25, 2026
|
The BioNTX iC³ Life Science & Healthcare Innovation Summit is North Texas’s premier convening for the region’s bioscience and healthcare community. Each year, we bring together industry leaders, pioneering researchers, investors, entrepreneurs, and innovators to share insights, explore emerging trends, and collaborate on the next breakthroughs in life sciences and healthcare.
At iC³ 2026, you will have the opportunity to engage with thought leaders, connect with peers, and participate in conversations that are shaping the future of healthcare innovation in North Texas and beyond. Whether you are looking to gain knowledge, showcase your work, or build meaningful partnerships, iC³ provides the platform to make an impact.
|
Thank you for your support
|
iC³ Hotel Room Block
BioNTX has secured a discounted room block at the Drury Plaza for the iC³ Summit,
please feel free to take advantage of this hotel during your stay.
|
Drury Plaza Hotel Dallas Arlington
101 West Road to Six Flags Street
Arlington TX 76011
|
BIO BREAK: Connect, Collaborate, Innovate
|
BIO BREAK brings the life sciences community together for an evening of connection and conversation. Attendees will have the opportunity to network with peers, share insights on emerging trends, and explore ideas driving collaboration and innovation across the ecosystem. The event is designed to strengthen professional relationships and support a more connected life sciences community in the region.
|
FORT WORTH
October 13, 2026
|
Exclusive BioNTX Member Benefit:
Save 10% on TechFW ThinkLab OnDemand
|
BioNTX members receive an exclusive 10% discount on TechFW's ThinkLab OnDemand, a self-paced startup accelerator designed to help founders take their ideas from concept to investor-ready venture.
Through eight guided modules, participants validate their business idea, refine their value proposition, develop a go-to-market strategy, explore funding options, and build a compelling investor pitch.
|
Alloy Introduces a New Model for Accelerating Drug Development
|
Alloy is introducing a new biotech model called a Product Development Organization (PDO), designed to provide integrated drug development capabilities from discovery through commercialization without competing with its partners. Unlike traditional service providers or pharmaceutical companies with their own pipelines, Alloy offers a neutral platform combining infrastructure, proprietary data, and expertise to help innovators advance medicines faster.
|
AstraZeneca’s Enhertu Combination Advances Toward
New Standard of Care in HER2-Positive Breast Cancer
|
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab received a positive recommendation from the European Medicines Agency for first-line treatment of HER2-positive metastatic breast cancer. Results from the DESTINY-Breast09 Phase III trial showed the therapy reduced the risk of disease progression or death by 44% and extended progression-free survival beyond three years, marking a potential advancement in care for patients with this aggressive cancer subtype.
|
BA Sciences Expands North Carolina Laboratory
to Enhance Analytical Capabilities
|
BA Sciences has expanded its North Carolina laboratory to increase capacity and strengthen its environmental monitoring capabilities. The investment adds dedicated space and enhanced analytical resources to better support clients with evolving needs through tailored solutions, scientific expertise, and scalable laboratory support.
|
Johnson & Johnson Receives FDA Authorization
for OTTAVA™ Robotic Surgical System
|
Johnson & Johnson’s OTTAVA™ Robotic Surgical System has received FDA De Novo authorization, becoming the first table-integrated soft tissue robotic system approved for multiple general surgery procedures. The system marks a new advancement in surgical robotics, combining integrated technology and clinical insights to support the future of minimally invasive care.
|
Secretome Therapeutics Expands Leadership Team
to Advance Rare Disease Pipeline
|
Secretome Therapeutics has expanded its executive leadership team with key appointments across clinical development, operations, medical affairs, and finance to support the company’s growth as a rare disease-focused biopharma. The leadership changes will help advance STM-01, a regenerative therapy in development for Duchenne muscular dystrophy, while continuing to expand Secretome’s platform of novel cell-based therapies.
|
McMillan James Equipment Company Expands Texas Offerings Through Partnership with Canature WaterGroup Commercial
|
McMillan James Equipment Company has announced a new partnership with Canature WaterGroup Commercial, a leader in commercial water treatment solutions. Through this collaboration, MJEC will add Canature’s innovative water treatment technologies to its Texas line card, providing contractors, engineers, and end users with expanded access to high-performance solutions backed by MJEC’s local expertise, technical resources, and customer-focused service. The partnership strengthens MJEC’s ability to deliver comprehensive building solutions and support the evolving needs of customers across the state.
|
UNT Health Researcher Explores How the Nose May
Influence Human Temperature Regulation
|
A PhD researcher at UNT Health Fort Worth is investigating how the size and shape of the nose may impact the body’s ability to regulate heat. Using advanced tools, including a climate chamber and CT imaging, the research explores the role of the respiratory system in thermoregulation and how nasal anatomy may help humans adapt to different environments.
|
UTA Students Win National Award for
Wearable Robotic Device Supporting Stroke Recovery
|
Two University of Texas at Arlington undergraduates earned first place in the 2026 National Academy of Inventors GenSpiration Prize Competition for developing a lightweight, wearable soft robotic wrist exoskeleton. The innovative device uses advanced robotics to support stroke survivors in regaining wrist function while offering a more portable and adaptable approach to rehabilitation.
|
UT Dallas Researcher Receives CPRIT Support
to Advance Rare Cancer Treatments
|
University of Texas at Dallas bioengineering researcher Dr. Yi Li has received support from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance new treatments for solitary fibrous tumor, a rare cancer driven by gene fusions. The research will explore innovative approaches, including immunotherapy and gene-targeting therapies, with the potential to improve treatment options for SFT and other gene fusion-driven cancers.
|
UT Southwestern Ranked No. 1 Healthcare Institution
Worldwide for Research Impact
|
UT Southwestern Medical Center has been ranked the No. 1 healthcare institution worldwide by Nature Index for high-quality research publications across all subjects. The recognition highlights UTSW’s continued leadership in biomedical discovery, with research spanning cancer, neuroscience, cardiovascular health, metabolic disease, and other areas advancing scientific knowledge and patient care.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
Global Development Initiative (GDI) Program
The GDI Program helps foreign companies successfully enter the U.S. market by providing valuable market research, industry insights, and strategic recommendations. Companies gain a better understanding of customers, competitors, opportunities, and potential challenges to make informed market entry decisions.
Applications closes on August 22, 2026
|
UT Dallas Biotech Club Seeking Project Partners
The UT Dallas Biotech Club is seeking biotech companies, startups, and research labs interested in partnering with teams of talented engineering and computer science students for semester-long projects. This no-cost program provides organizations with additional technical support while giving students valuable hands-on industry experience.
Applications closes on August 30, 2026
|
The Harrington Prize for Innovation in Medicine
The Harrington Prize for Innovation in Medicine, presented by the American Society for Clinical Investigation and Harrington Discovery Institute, honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application.
Applications closes on September 14, 2026
|
FDA READI-Home Innovation Challenge
The FDA’s READI-Home Innovation Challenge supports innovators developing medical device technologies that can be used in the home setting to help reduce hospital readmissions. Selected participants will have the opportunity to engage with the FDA, gain early regulatory insights, and advance solutions that improve patient care after hospital discharge.
Applications closes on September 30, 2026
|
Upcoming Events & Opportunities
|
Nucleate Global Summit 2026
This Nucleate Global Summit is an environment where founders, scientists, and investors from around the world can engage in conversations, share real challenges, and build relationships that extend far beyond Summit.
August 16th - 18th | Parker, TX
|
The Future Biotech Expo is the United States' dedicated international exhibition and conference for red biotechnology, the science at the intersection of biology and human health.
August 19th - 20th | Houston, TX
|
Cell & Gene Therapy Symposium 2026
Join Sino Biological at the Houston Cell & Gene Therapy Symposium 2026, a premier gathering of leading scientists, researchers, and industry professionals in the field of cell and gene therapy.
August 21st | Houston, TX
|
Texas Cardiovascular Innovations Conference
The Texas Cardiovascular Innovations Conference is a premier event delivering the latest advancements and education in cardiovascular care. .
August 21st - 22nd | Houston, TX
|
Thank you for your support!
|
|
